- AstraZeneca Plc AZN announced detailed results from the SERENA-2 Phase 2 trial of camizestrant in pretreated post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer.
- The data showed that camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) at 75mg and 150mg dose levels versus Faslodex (fulvestrant) 500mg in patients previously treated with endocrine therapy.
- In the overall population, camizestrant significantly reduced the risk of disease progression or death by 42% at a 75mg dose with a median PFS of 7.2 versus 3.7 months and 33% at a 150mg dose with median PFS of 7.7 versus 3.7 months compared to Faslodex, the current SERD standard of care.
- Among the prespecified subgroup of patients with ESR1 mutations, camizestrant showed a 67% reduction in the risk of disease progression or death at a 75mg dose and a 45% reduction at a 150mg dose.
- The company also announced detailed results from the CAPItello-291 Phase 3 trial of capivasertib + Faslodex (fulvestrant) combo in patients with hormone receptor (HR)-positive, HER2-low or negative, locally advanced or metastatic breast cancer.
- Results showed capivasertib in combination with Faslodex demonstrated a 40% reduction in the risk of disease progression or death versus placebo plus Faslodex in the overall trial population.
- Price Action: AZN shares are up 0.75% at $69.36 on the last check Thursday.
- Photo Via Wikimedia Commons
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
